Hinge Bio is a startup. Brouky records 1 investor associated with the company.
Hinge Bio develops a broadly applicable biologics platform to generate therapeutic candidates across rare disease, oncology, and immunology indications. The company is listed as preclinical and active on the investor's portfolio page.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.